NSTEMI (Non-ST-segment elevation myocardial infarction)

Find all the latest content on NSTEMI published on this website.

NSTEMI is considered one of the leading causes of morbidity and mortality and its definition and treatment remains challenging requiring specific, adapted responses. Understanding different biomarkers, becoming aware of emerging new agents used in adjunctive pharmacotherapy, keeping abreast of advances in imaging techniques as well as the use of invasive imaging and functional assessment is critical. Tools, devices and techniques, and complications such as different types of vascular access or bleeding risks, can also be found here…

Filtered By
NSTEMI

298 results

COVID-19: Providing ongoing care to patients with cardiovascular disease in a pandemic

20 Mar 2020

The world is facing unprecedented challenges as a result of a bug called COVID-19 (Sars-CoV-2) that has literally gone “viral” across the globe affecting >250K individuals in 183/195 countries, claiming >10,000 lives in a short period of time (as of 15:00 20/3/2020). 

Vijay Kunadian

Author

Vijay Kunadian
COVID19

Morphine and cardiovascular outcomes among patients with non-ST-segment elevation acute coronary syndromes undergoing coronary angiography

17 Feb 2020

EARLY ACS was a randomised control trial assessing early versus delayed use of eptifibatide in patients presenting with NSTE-ACS and high-risk features. In this subanalysis, the authors evaluate the association between morphine and ischaemic events in patients pre-treated with clopidogrel.

Nicola Ryan

Reviewer

Nicola Ryan
Dejan Milasinovic

Reviewer

Dejan Milasinovic
Morphine and cardiovascular outcomes among patients with non-ST-Segment elevation ACS undergoing coronary angiography

Interactive Case Corner 1 - Thrombosed AVG, bifurcation lesions & diffuse CAD

18 Dec 2019 – From GulfPCR-GIM 2019

Consult this session to discover a selection of challenging clinical cases, such as myocardial revascularisation in diffuse CAD, PCI of bifurcation lesion with DK crush technique, angioplasty of totally thrombosed arteriovenous graft, and more!

Interactive Case Corner 1 - Thrombosed AVG, bifurcation lesions & diffuse CAD

Interactive Case Corner 5 - Coronary CTO & ACS NSTEMI

18 Dec 2019 – From GulfPCR-GIM 2019

Consult this session to discover two clinical cases on coronary CTO and ACS NSTEMI, and learn how to reduce radiation exposure to the patient during the procedure.

Interactive Case Corner 5 - Coronary CTO & ACS NSTEMI

Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting

10 Nov 2019

One of the most discussed limitations of GLOBAL-LEADER is the lack of event adjudication so that the rate of MI, bleeding or stent thrombosis between the two groups were unknown. In this study, events were adjudicated in those patients from the 20 top-enrolling participating sites.

Reviewer

Salvatore Brugaletta
Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting

An NSTEMI case due to a severe LM calcific sub-occlusive stenosis

22 Oct 2019

View this case of an 85-year-old woman, hypertensive under medical therapy with no previous medical or surgical history, who called the emergency services about chest pain and shortness of breath...

Author

Flavio Luciano Ribichini
NSTEMI case due to a severe LM calcific sub-occlusive stenosis

Ticagrelor with or without aspirin in high-risk patients after PCI

07 Oct 2019

The TWILIGHT trial was designed to test the hypothesis that in patients undergoing PCI who are at high risk for ischemic or hemorrhagic complications and who have completed a 3-month course of DAPT with ticagrelor plus aspirin, continued treatment with ticagrelor monotherapy would be superior to ticagrelor...

Elad Asher

Reviewer

Elad Asher
Ticagrelor with or without aspirin in high-risk patients after PCI

ISAR REACT 5 - Ticagrelor versus prasugrel in patients with acute coronary syndrome

03 Sep 2019

At the ESC Congress 2019 in Paris, Stefanie Schuepke presented the results of the ISAR REACT 5 study. Read this analysis by Francesco Costa and view a short interview with Stefanie Schuepke.

Francesco Costa

Author

Francesco Costa
ISAR REACT 5 - Ticagrelor vs prasugrel in patients with acute coronary syndrome

Rapid NSTEMI Pathways in 2019: why every PCI centre needs one and how to set it up

Patrick Calvert (UK) explains to Dejan Milasinovic (Serbia) how his centre has set up a protocol to treat high-risk NSTEMI patients with the aim of achieving the guideline recommended time of 24 hours from presentation to Cathlab. They discuss the design of the system and what...

Rapid NSTEMI Pathways in 2019: why every PCI centre needs one and how to set it up

Mechanical circulatory support devices to protect patients during high-risk PCI

Performing high-risk percutaneous coronary intervention (PCI) in complex patients requires the interventional cardiologist to use mechanical circulatory support devices to achieve safer outcomes. Which patients are most at risk of complex PCI? What are the best mechanical circulatory support devices currently available and which has the strongest...

Mechanical circulatory support devices to protect patients during high-risk PCI

Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention

09 Jul 2019

Results of the SMART-CHOICE randomized clinical trial

Daniele Giacoppo

Reviewer

Daniele Giacoppo
Effect of P2Y12 inhibitor monotherapy vs DAPT on cardiovascular events in patients undergoing percutaneous coronary intervention

Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI

09 Jul 2019

Results of the STOPDAPT-2 randomized clinical trial

Daniele Giacoppo

Reviewer

Daniele Giacoppo
Effect of 1-month DAPT followed by clopidogrel vs 12-month DAPT on cardiovascular and bleeding events in patients receiving PCI

How should I treat a myocardial infarction with nonobstructive coronary arteries (MINOCA) in a young patient?

01 Jul 2019

A 20-year-old male with no history of previous illness presented to the emergency department because of chest pain that had started around three hours after physical exercise (soccer match)...

A young patient with spontaneous proximal LAD thrombosis

All you need to know about physiology

04 Jul 2019 – From AICT-AsiaPCR 2019

Consult this session to gain an update on physiology assessment options, learn more about how to correctly perform, interpret and implement physiology based assessments, and discover all about the future perspectives in this field.

All you need to know about physiology

Extended DAPT: who & how can PEGASUS be applied in clinical practice?

04 Jul 2019 – From AICT-AsiaPCR 2019

Consult this session to learn more about PEGASUS, a trial designed to evaluate the potential benefit of DAPT beyond 1 year after a myocardial infarction, with or without stent implantation: to whom & how can extended DAPT be applied in clinical practice? Discover it now!

Extended DAPT: who & how can PEGASUS be applied in clinical practice?

What every interventional cardiologist should know about new cardiovascular drugs

Hannah McConkey (UK) talks to cardiologist and pharmacologist Atul Pathak (France) about the important changes in recent drug therapy. They discuss the easy-to-use lipid-lowering PCSK9 inhibitors, and ask should cardiologists now be prescribing the new classes of antidiabetic drugs? The key messages in antithrombotic therapy, and how to...

What every interventional cardiologist should know about new cardiovascular drugs

Prognostic implications of plaque characteristics and stenosis severity in patients with coronary artery disease

03 Jun 2019

Elad Asher

Reviewer

Elad Asher

Reviewer

Salvatore Brugaletta
Prognostic implications of plaque characteristics and stenosis severity in patients with CAD

Trials and registries - Managing bleeding risk in search of optimal drug-device synergy

23 May 2019 – From EuroPCR 2019

Consult this session to discover the results of the latest trials and registries for the management of bleeding risk in search of optimal drug-device synergy: ROBOT-ACS, GLOBAL LEADERS, SAFE-A, and more!

Trials and registries - Managing bleeding risk in search of optimal drug-device synergy

Bridging the gap of oral P2Y12 inhibition for PCI with cangrelor: what does the new data tell us?

22 May 2019 – From EuroPCR 2019

Consult this session to learn through studies and clinical cases more about contemporary pharmacological strategies with intravenous antiplatelet therapy in PCI for STEMI, NSTEMI and complex stable coronary artery disease patients.

Bridging the gap of oral P2Y12 inhibition for PCI with cangrelor: what does the new data tell us?

Different approaches to challenging NSTEMI cases

22 May 2019 – From EuroPCR 2019

Consult this session to learn all about tactical and strategic approaches to the invasive treatment on NSTEMI and to discover challenging clinical cases on NSTEMI.

Different approaches to challenging NSTEMI cases